Subject: ESIV Issues Corporate Update MJNA Up 3rd Day in a Row

SCV Client Spotlight
ESIV Issues Corporate Update MJNA Up 3rd Day in a Row
Top PerformerYesterday's Top Performer

Medical Marijuana Inc. (Pink Sheets: MJNA)

End of Day:

Price: 0.131

Change (%): + 0.022 (20.18)

Volume: 8,076,052
MJNA Chart

Amendment 37 Helps Plant Hemp in the U.S

An amendment that would allow colleges and universities to grow and cultivate industrial hemp for academic and agricultural research purposes was approved by the House Rules Committee for inclusion in the 2013 “farm bill” (H.R. 1947 Federal Agricultural Reform and Risk Management Act or FARRM). Amendment 37 was passed by a majority of House Reps voted in favor of colleges and universities being allowed to study industrial hemp before the entire 2013 FARRM Act was struck down.

Sponsored by Representatives Jared Polis (D-CO) and Thomas Massie (R-KY), this amendment is the first time that industrial hemp has been put to a vote in any fashion in Washington since World War II.

Continue Reading

Hot Stock to WatchHot Stock to Watch

Essential Innovations Technology Corp. (OTCQB: ESIV)

End of Day:

Price: 0.17

Change (%): + 0 (0.00)

Volume: 25,900
ESIV Chart

Essential Innovations Technology Corp.: Current Corporate Initiatives

HONG KONG-(Marketwired - Jun 25, 2013) - Essential Innovations Technology Corp. (OTCBB: ESIV) (OTCQB: ESIV) is truly pleased to be able to provide the following update to the investment community:

Jason McDiarmid, President/CEO, states, “The Company is making substantial progress towards achieving our current corporate initiatives. We are in the process of negotiating and finalizing exclusive distribution rights to represent equipment manufactured by one of China’s top HVAC manufacturers, for the countries of the Philippines, Dubai and the UAE. In support of the launch of equipment sales and marketing in each of these countries, the Company intends to exhibit in the largest HVAC conferences each has to offer later this calendar year. In addition, with the assistance of our strategic advisory board, the Company is endeavoring to facilitate the establishment of an internationally recognized industry association in each of these countries to enhance product reputation and credibility. The Company continues to move forward with development of the unique and disruptive ‘Eximius Technologies’ to which it owns the exclusive worldwide rights. We are undertaking to submit for full patent-protection in the near-term for both the ‘Cavitator’ and the ‘Resonator’ with the USPTO and we have further accessed additional technologies of interest, to which similar exclusive worldwide rights are being sought.

Continue Reading

Other Small Cap News

Company: Limitless Venture Group Inc. (Pink Sheets: LVGI)

LVGI’s Genetically Enhanced Anabolic Research Inc. (G.E.A.R.) Sports Nutraceuticals Subsidiary Introduces their Shock Series™ Product Line with BEET DRIVE™ Technology

First of Its Kind, Patent-Pending Performance Technology to Initially Include Three Products That Focus on Timing Windows for Maximum Work-Out Performance, Sustentation and Recovery

Holbrook, NY, June 24, 2013 -- Limitless Venture Group Inc. (OTC Pink: LVGI) today announced, through its G.E.A.R sports nutraceuticals subsidiary, the introduction of its revolutionary Shock Series product line with patent-pending BEET DRIVE Technology. The initial workout line of supplements will consist of three products that focus on timing windows for maximum work out performance, sustentation and recovery.

Continue Reading

Company: Nuvilex (OTCQB: NVLX)

Nuvilex Primed to Succeed Where Others Have Failed

BALTIMORE, MD--(Marketwired - Jun 25, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that as Nuvilex (OTCQB: NVLX) continues on to the next phase of development following successful Phase II clinical trials to treat advanced inoperable pancreatic cancer, we may perhaps be witnessing the dawn of a new universal cancer therapy potentially worth billions of dollars.

The proliferation of early cancer screening and the cessation of smoking have been universal methods which have been used in recent years to prevent cancer. Yet, despite spending over 100+ billion in funding cancer research and development projects by private industry and quasi-government organizations, there is no universally approved therapy. Moreover, most of the treatments today are akin to poison, as they are toxic to healthy cells as well as cancer cells and often cause such severe side effects that some patients opt out of the treatment altogether.

Continue Reading

Market News

By Dan Berman: Hot Stock Minute

Fed or People’s Bank of China: Whose Policies Worry You More?

The Fed or the People's Bank of China: Whose Policies Worry You More? Vote below in the daily "Hot Stock Minute" poll. But first, listen to Yahoo! Finance's Lauren Lyster and Mike Santoli discuss what's going on with both banks. The pair also talk about the economic data being released today and the effect the market pullback is having on IPOs.

Continue Reading

By Leah Schnurr:

Home prices see biggest annual gain in seven years in April: S&P

NEW YORK (Reuters) - Single-family home prices jumped in April, racking up their biggest annual gain in seven years in a sign of growing momentum in the housing recovery, a closely watched survey showed on Tuesday.

The S&P/Case Shiller composite index of 20 metropolitan areas gained 1.7 percent on a seasonally adjusted basis, topping forecasts for 1.2 percent.

Prices in the 20 cities accelerated by 12.1 percent year over year, which was also above expectations and the biggest annual gain since March 2006.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the "unsubscribe" link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks